Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation

NCT06005974 is registered in ClinicalTrials.gov with Recursion Pharmaceuticals Inc. as lead sponsor.

NCT NCT06005974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06005974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation
Lead sponsor
Recursion Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 15, 2024
Completion date
February 24, 2025
Enrollment
18 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

apc gene mutation, axin1 gene mutation, solid tumor